Quantitative real time PCR assay for detecting EBV virus in multiple sample types. by Stevenson, Jeffery B.
 We are developing a real time quantitative PCR assay to detect EBV in serum, plasma, whole blood, tissue and spinal fluid.  Real time PCR, with its intrinsic quantitative capacity, is an excellent method 
for measuring EBV viral load. Epstein Barr virus is a member of the Herpesvirus family, with a tropism for B lymphocytes, where it establishes latency. In transplant settings, it causes post transplantation 
lymphoproliferative disorder (PTLD). High doses of immunosuppressive drugs allow the virus to escape the immune system, which normally keeps the latent virus in check. Symptoms of PTLD can mimic 
those of organ rejection, leading to increased immunosuppression, when a decrease in dosage is actually necessary.
  The primers and probes for this assay are supplied by Epoch/Nanogen and target a region of the BNFR1 gene. This EBV assay design has the probe-binding site overlapping one of the primer binding 
sites by five nucleotides. Dilutions of a plasmid containing the cloned amplicon are used as standards. A new standard curve is generated and stored with each new lot of EBV reagents or Taq polymerase. 
Sequestration of reagent lots and the lyophilization of control material have been shown to help maintain stability of assay performance over the period that a stored standard curve is being used. A 
plasmid internal control is included in the sample extraction to detect PCR inhibition and extraction failures. 
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MATERIALS and METHODS
Extractions:  
 Extractions were performed on the Qiagen 9604 Robot using the recommended protocol.  Internal control 
plasmid is added to the lysis buffer to give a final concentration in the extracted samples of 100 copies per  L 
(=1000 copies per 10  L extracted sample).
Amplification and detection:
 The EBV primer and probe reagents are provided by Nanogen/Epoch Biosciences and include primers and 
probe for amplification of an internal control plasmid. In contrast to previously described Eclipse probes, which 
have the fluorescent dye on the 3' end, the EBV and internal control probes used in this assay have the 
fluorescent dye (FAM or PY559, respectively) on the 5' end, with the quenching molecule on the 3' end.  This 
inverted orientation provides for lower background fluorescent signal and increased solubility. The EBV probe 
is labeled at the 5' end with FAM and a minor groove binding molecule (MGB).  The 3' end of the EBV probe is 
labeled with a non-fluorescent quencher (NFQ).  The internal control probe is also labeled at the 3' end with a 
non-fluorescent quencher.  It is labeled at the 5' end with a fluorescent dye, PY559, and the MGB.  The asterisks 
in the probe sequences indicate guanosines that have been chemically modified to prevent probe aggregation 
and quenching of the fluorescent dye.  Red indicates primer sequences, green indicates EBV probe sequence, 
purple indicates internal control probe sequence, and nucleotides in blue indicate regions where a primer and 
probe sequence overlap.  The 'K' in the EBV target sequence indicates the position of a polymorphism (either a 
T or a G); the 'M' in the corresponding EBV downstream primer indicates the position of a degenerate base.  
The EBV primers for this assay have a non-templated, 12 nucleotide AT-rich tail added to their 5' ends (in 
yellow) that increases PCR efficiency and the quantity of product generated.
EBV:
  upstream primer:  5' - AATAAATCATAAGTTAATCCGATCTGGTCGCA - 3'
 downstream primer:  5' - AATAAATCATAAGAACCTGGTCMTCCTTTG - 3'
 probe:  5' - MGB - FAM - G*TACG*AGTG*CCTG*CG*A - NFQ - 3'
IC:
 upstream primer:  5' - GCAATCGTATTACCTCTTATCGCAG - 3'
 downstream primer:  5' - CAACCATCGTCATCGTCAGGAAAC - 3'
 probe:  5' - MGB - PY559 - G*CAAAGTCCCATCGTT- NFQ - 3'
GTTAATCCGATCTGGTCGCAGGCACTCGTACTGCTCGCTGGCAAAGGAKGACCAGGTTC
GCAATCGTATTACCTCTTATCGCAGCTGGTTCCTATTTGGCAAAGTCCCATCGTTTCCTGACGATGACGATGGTTG
We perform the assay using 10✁L of extracted DNA in a 50✁L 
total reaction volume.  In addition to the target DNA, we include the 
following reagents:
    
    EBV/IC primer mix
    EBV/IC probe mix
    MgCl2
    UNG (Perkin Elmer)
    LC FastStart Hyb Probe Mix (Roche)     
    PCR Enhancer (Epicentre)
    ROX
The final reaction concentration of the primers is 1 
✂
M each for the 
EBV primers and 300 nM each for the internal control primers.  Both 










The cycling conditions for amplification 
and detection are as follows:
 1)  50oC        2 minutes
      2)  95oC        8 minutes
      3)  95oC        15 seconds 
     4)  58oC        30 seconds
 5)  76oC        30 seconds
 6)  95oC        15 seconds
 7)  45oC        15 seconds
 8)  95oC        15 seconds
All ramp rates are set to 100%, except
for the final ramp which is set to 5%.  
Data is collected at step 4 and during 
the temperature ramp between steps
7 and 8.
Table 1
Sample initial testing repeat testing
whole blood  1 2.7 3.4
whole blood  2 neg neg
whole blood  3 neg 2.1
whole blood  4 neg neg
whole blood  5 neg neg
whole blood  6 4.9 4.5
whole blood  7 4.3 3.6
whole blood  8 neg neg
whole blood  9 neg neg
whole blood  10 neg neg
whole blood  11 neg neg
whole blood  12 neg neg
whole blood  13 3.2 neg, 2.2
whole blood  14 2.9 3.1
whole blood  15 3.7 3.2
whole blood  16 neg neg
whole blood  17 3.1 2.8
whole blood  18 neg neg
whole blood  19 3.3 2.3
whole blood  20 neg neg
whole blood 22 3.3 2.8
whole blood 23 3.1 3.0
whole blood 24 neg 2.5
EBV viral load (log copies/mL)
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     RESULTS
 We made log dilutions of our standard (a plasmid containing the cloned amplicon) and tested 
them in our assay.  The EBV amplification plot is shown in Figure 1, while the amplification plot 
for the internal control is shown in Figure 2.  The internal control C
t
 is unchanged over 6 logs of 
target concentration.  The melting temperature of the probe is approximately 69oC (Figure 3). We 
generated a 6 log standard curve (Figure 4) with a range of 10 to 1,000,000 copies per reaction 
(390 to 39,000,000 copies per mL). The slope of the standard curve was -3.52 (PCR efficiency = 
92%) with an R2 value of 0.997.  When we compared the sensitivity of this new assay with that of 
the LightCycler assay currently used in our clinical lab, by testing serial 2-fold dilutions of con-
trol material, that both assays displayed approximately equal sensitivity.
 To evaluate the accuracy of the assay, we tested 66 plasma and serum samples (and one 
whole blood) that had been previously quantitated at a major reference lab.  The results of this 
comparison are shown in Table 1.  Our Eclipse assay generated consistently higher quantitative 
values than those of the reference lab, by approximately 0.5 log (mean difference = 0.6 log). Re-
gardless of the quantitative values generated, these 2 assays display good agreement when 
qualitative results are examined, indicating that the limits of detection are likely similar for both 
methods.  Of the 67 samples tested, both methods were in agreement for 59 (88%).  The other 8 
samples (highlighted in yellow) were low positives, with an even distribution between those that 
went undetected at ARUP and those that went undetected at the reference lab.  These results 
suggest that differences in the standard material may be responsible for the differences in the 
quantitative values generated by each assay.  These differences are currently being explored. 
 As part of our initial validation, we tested 23 randomly selected whole blood samples that had 
been sent to ARUP for testing (Table 2).  Interestingly, nearly 40% (9/23) were reproducibly posi-
tive by our assay. Another 3 (highlighted in yellow) gave indeterminate results, consistent with 
these samples being low positives, near our limit of detection.
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Y-int:    42.8
R
2
:        0.997
eff:       92%
CONCLUSIONS
Measuring EBV viral load in transplant patients is an 
important element in determining the course of 
treatment.  This test is linear over 6 logs and has an 
analytical sensitivity approaching that imposed by 
sampling error.  Use of a hybridization probe provides 
the opportunity to perform a melt curve analysis, which 
can aid in preventing false negatives due to sequence 
variations in the target.  Accurate quantitative PCR 
requires accurate quantitation of standard material. The 
differences between results from the ARUP assay and 
that of our reference lab are not likely due to differences 
in sensitivity, but small differences in the quantitation of 
standards at each laboratory.  This emphasizes the need 
for a common standard material that can be used to 
improve the consistency of results between labs.
Sample initial testing repeat testing reference lab result sample type
JSEBV 101905-01 3.7 3.6 2.3 plasma
JSEBV 101905-02 4.5 3.9 plasma
JSEBV 101905-03 3.7 4.0 2.3 plasma
JSEBV 101905-04 3.7 3.3 2.8 plasma
JSEBV 101905-05 neg 2.9, neg 2.8 serum
JSEBV 101905-06 neg <2.0 plasma
JSEBV 101905-07 2.1 2.5 plasma
JSEBV 101905-08 3.9 3.7 3.2 plasma
JSEBV 101905-09 3.4 3.0 plasma
JSEBV 101905-10 2.9 2.6 2.0 plasma
JSEBV 101905-11 2.8 2.3 plasma
JSEBV 101905-12 3.6 3.0 plasma
JSEBV 101905-13 3.6 3.3 plasma
JSEBV 101905-14 2.6 2.3 plasma
JSEBV 101905-15 neg 3.3, 2.7 2.0 serum
JSEBV 101905-16 neg <2.0 plasma
JSEBV 101905-17 3.5 3.7 2.3 plasma
JSEBV 101905-18 3.8 3.5 plasma
JSEBV 101905-19 3.9 3.4 plasma
JSEBV 101905-20 3.4 3.7 2.7 plasma
JSEBV 101905-21 2.6 2.4 2.0 plasma
JSEBV 101905-22 3.7 3.5 3.0 plasma
JS-EBV080405-1 neg <2.0 serum
JS-EBV080405-2 neg <2.0 serum
JS-EBV080405-3 neg <2.0 serum
JS-EBV080405-4 neg <2.0 serum
JS-EBV080405-5 neg <2.0 serum
JS-EBV080405-6 neg <2.0 serum
JS-EBV080405-7 neg <2.0 serum
JS-EBV080405-8 neg <2.0 serum
JS-EBV080405-9 neg <2.0 serum
JS-EBV080405-10 neg <2.0 serum
JS-EBV080405-11 2.9 2.4 <2.0 serum
JS-EBV080405-12 neg <2.0 serum
JS-EBV080405-13 2.3 neg, 2.0 <2.0 serum
JS-EBV080405-14 neg <2.0 serum
JS-EBV080405-15 neg <2.0 serum
JS-EBV080405-16 4.9 4.3 whole blood
JS-EBV080405-17 2.6 2.6 serum
JS-EBV080405-18 3.4 2.9 2.6 serum
JS-EBV080405-19 4.5 4.2 3.0 serum
JS-EBV080405-20 3.1 2.6 2.5 serum
JS-EBV080405-21 3.3 3.2 serum
JS-EBV080405-22 2.9 2.0 2.3 serum
JS-EBV080405-23 neg neg 3.1 serum
JS-EBV080405-24 3.6 3.9 serum
JS-EBV080405-25 3.8 3.0 3.1 serum
JS-EBV080405-26 4.4 4.0 3.6 serum
JS-EBV080405-27 2.7 2.7 2.0 plasma
JS-EBV080405-28 2.4 2.4 <2.0 plasma
JS-EBV080405-29 3.2 2.6 2.3 plasma
JS-EBV080405-30 2.3 2.0 plasma
JS-EBV080405-31 neg <2.0 plasma
JS-EBV080405-32 neg <2.0 plasma
JS-EBV080405-33 neg <2.0 plasma
JS-EBV080405-34 neg neg 2.0 plasma
JS-EBV080405-35 3.7 3.0 2.5 plasma
JS-EBV080405-36 neg <2.0 plasma
JS-EBV080405-37 neg <2.0 plasma
JS-EBV080405-38 neg <2.0 plasma
JS-EBV080405-39 3.5 3.1 2.8 plasma
JS-EBV080405-40 neg <2.0 plasma
JS-EBV080405-41 neg <2.0 plasma
JS-EBV080405-42 neg <2.0 plasma
JS-EBV080405-43 neg <2.0 plasma
JS-EBV080405-44 neg <2.0 plasma
JS-EBV080405-45 2.7 neg <2.0 plasma
EBV viral load (log copies/mL
